New vaccine combo targets tough cancers in early trial
NCT ID NCT04117087
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-phase study tests a vaccine targeting mutant KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with resected pancreatic or colorectal cancer. The goal is to see if the combination is safe and boosts the immune system's ability to fight cancer cells. Participants must have completed prior treatments and have no current evidence of disease (for pancreatic cancer) or have had at least two prior chemotherapy regimens (for colorectal cancer).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.